C Roux

No ORCID on file · 5 papers in corpus · active 1995-2004

Study types

  • article 2
  • other 2
  • rct 1

Condition tags

  • endometriosis 5
article 2004
Human Reproduction ·doi:10.1093/humrep/deh250

BACKGROUND: It has been proposed that hormonal supplementation during prolonged GnRH agonist therapy prevents hypoestrogenic side effects, including bone loss. The optimal combination for long-term treatments with safe metabolic profile rem…

rct 1998
Calcified tissue international ·doi:10.1007/s002239900388

To evaluate bone biochemical markers as predictors of the efficacy of a hormone replacement therapy (HRT), we studied the bone changes induced by the cessation and return of ovarian function in 28 patients treated for 6 months with a GnRH a…

other 1997
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA ·doi:10.1007/s001980050034

This prospective longitudinal study was undertaken to examine the short-term effects (6 months) of estrogen withdrawal on the circulating IGF system. A series of 40 patients suffering from endometriosis was studied before and after a 6-mont…

other 1995
Fertility and Sterility ·doi:10.1016/s0015-0282(16)57557-8

OBJECTIVE: To evaluate the teratogenic or fetal risk of a long-acting GnRH agonist (GnRH-a) triptoreline acetate (Decapeptyl; Ipsen-Biotech, Inc., Paris, France), inadvertently administrated in the first weeks of pregnancy. DESIGN: Prospec…

article 1995
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA ·doi:10.1007/bf02106098